Improving Survival Rates and Mitigating Adverse Events with Immunotherapies in Advanced Melanoma
Pre-Test

Questions marked with a * are required
100%
Contact Information
Based on evidence, which of the following is TRUE about combination immunotherapy for advanced melanoma? 
Based on evidence and guidelines, which of the following is a preferred first-line treatment for metastatic or unresectable melanoma? 
A 68-year-old patient with advanced melanoma was recently put on combination immunotherapy with nivolumab and ipilimumab, but developed diarrhea with ten bowel movements per day after three cycles of therapy. Which course of action would you consider for this patient? 
A 56-year-old patient with newly diagnosed BRAF V600E metastatic melanoma with brain lesions. Upon consultation with your team, which of the following would you offer to this patient? 
A 72-year-old patient with a history of sun exposure, prior history of stage IIIB resected melanoma that deferred initial adjuvant therapy, now has disease recurrence with node and lung metastasis with high LDH (BRAF wild-type). What would you do next? 
Powered by QuestionPro